Vertex Pharmaceuticals Incorporated Q2 FY2025 earnings call

R&D Progress

• CF: ALYFTREK launched in multiple regions, NG 3.0 regimen nearing healthy volunteer study completion, and VX-522 trial restarted.
• Pain: FDA feedback on PNP program led to focus on DPN Phase III studies; VX-993 Phase II results showed no efficacy for acute pain monotherapy but continued DPN study planned.
• Type 1 Diabetes: Zimislecel nearing enrollment completion for pivotal study.
• Kidney Portfolio: Pove making progress in IgAN and membranous nephropathy trials; inaxaplin on track for interim analysis; VX-407 starting proof-of-concept trial.

Commercial Updates

• CF: ALYFTREK U.S. launch progressing well, CASGEVY global launch gaining momentum.
• JOURNAVX: U.S. launch saw progress in payer coverage, hospital uptake, and prescription fills, leading to increased commercial spend.

CSO Transition

• David Altshuler to retire in August 2026, with Mark Bunnage set to assume CSO role in February 2026, following a smooth transition plan.

Vertex reported $2.96 billion in revenue for the second quarter of 2025, representing a 12% year-over-year growth. Revenue from specific segments included $30 million from CASGEVY, $12 million from JOURNAVX, and $21 million from collaboration revenue. The CF franchise continued to grow with more eligible patients taking CFTR modulators, while CASGEVY saw global launch momentum and JOURNAVX had progress in its U.S. launch.

Vertex reiterated its 2025 financial guidance, including a total revenue range of $11.85 billion to $12 billion (representing ~8% growth at midpoint). Combined non-GAAP R&D, acquired IPR&D, and SG&A expenses are expected to fall in the range of $4.9 billion to $5 billion for the full year 2025, with the high end of the range anticipated. The company also announced a new $4 billion share repurchase program on top of an existing $3 billion program.

Potential risks include tariff uncertainties that could impact costs, regulatory hurdles in obtaining broad PNP labels for pain programs, and potential variability in CASGEVY revenue due to patient scheduling choices.

Q: About JOURNAVX commercial efforts and DPN trial enrollment A: Reshma noted the first DPN Phase III trial might enroll ahead of the second, and Duncan discussed JOURNAVX's progress in payer coverage and positive clinical feedback driving augmented commercial spend.

Q: On pain strategy and JOURNAVX gross to net A: Reshma outlined plans to secure a broad PNP label and Charles commented on gross to net normalization as payer coverage expands for JOURNAVX.

Q: On pain pipeline and 993 data A: Reshma discussed focusing on DPN first and then expanding to single indications for pain, and explained the implications of VX-993 Phase II results on acute pain modeling.

Q: On pove indications and JOURNAVX PSP A: Reshma explained pove indication prioritization based on unmet need, emerging data, and commercial potential, while Duncan discussed the phasing out of the patient support program for JOURNAVX as payer coverage increases.

Q: On JOURNAVX scripts and pove rationale A: Duncan provided details on JOURNAVX prescription split across retail and hospital settings, and Reshma explained pove's prioritization based on clinical data, preclinical insights, and commercial considerations.

Q: On JOURNAVX commercial lives and VX-828 A: Duncan discussed JOURNAVX's coverage of 150 million lives with 84 million having unrestricted access, and Reshma provided insights on VX-828's expected profile in CF treatment.

Q: On NOPAIN Act and CASGEVY cycle time A: Reshma addressed the NOPAIN Act draft rule and expectations for JOURNAVX's inclusion, and discussed plans to reduce CASGEVY's cycle time through operational improvements.

Q: On JOURNAVX inventory and 993 preclinical models A: Reshma confirmed no significant inventory for JOURNAVX and explained how VX-993 Phase II data refined preclinical models for Nav1.7 assets.

Q: On Medicaid MFN risk A: Reshma confirmed open communication with D.C. and no received letter regarding Medicaid Most Favored Nation concerns, indicating ongoing dialogue to address risks.